1. Home
  2. PRE vs SENS Comparison

PRE vs SENS Comparison

Compare PRE & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prenetics Global Limited

PRE

Prenetics Global Limited

HOLD

Current Price

$19.33

Market Cap

303.5M

Sector

Industrials

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$7.90

Market Cap

301.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRE
SENS
Founded
2014
1996
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Industrial Machinery/Components
Sector
Industrials
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
303.5M
301.2M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
PRE
SENS
Price
$19.33
$7.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$30.50
$18.38
AVG Volume (30 Days)
164.0K
638.7K
Earning Date
06-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,389,000.00
Revenue This Year
$108.69
$74.15
Revenue Next Year
$58.68
$58.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.85
52 Week Low
$7.18
$0.41
52 Week High
$23.63
$8.75

Technical Indicators

Market Signals
Indicator
PRE
SENS
Relative Strength Index (RSI) 56.22 75.53
Support Level $17.24 $7.35
Resistance Level $20.36 $8.49
Average True Range (ATR) 1.22 0.45
MACD 0.12 0.34
Stochastic Oscillator 81.43 78.53

Price Performance

Historical Comparison
PRE
SENS

About PRE Prenetics Global Limited

Prenetics Global Ltd is a consumer health and wellness company offering nutrition and longevity products through its flagship brand, IM8. It offers science-backed daily nutrition and longevity products distributed directly to consumers across multiple countries. The company's products are developed with scientific input and are subject to third-party quality certifications.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: